Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial

Background: The EGFR (epithelial growth factor receptor) ligands amphiregulin (AREG) and epiregulin (EREG) have been considered as predictors for EGFR-antibody efficacy. The effect of AREG and EREG expression levels in primary tumor samples on the outcome of bevacizumab-treated patients is unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Stintzing, Sebastian, Ivanova, Boryana, Ricard, Ingrid, Jung, Andreas, Kirchner, Thomas, Tannapfel, Andrea, Juette, Hendrik, Hegewisch-Becker, Susanna, Arnold, Dirk, Reinacher-Schick, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236022/
https://www.ncbi.nlm.nih.gov/pubmed/30467535
http://dx.doi.org/10.3389/fonc.2018.00474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236022/
https://www.ncbi.nlm.nih.gov/pubmed/30467535
http://dx.doi.org/10.3389/fonc.2018.00474

Ejemplares similares